<span id="midArticle_start"/>May 28 Adocia SA :
<span id="midArticle_0"/>* To present positive clinical results for BiochaperoneLispro
<span id="midArticle_1"/> <span class="first-article-divide"/>* "These results further confirm potential of our ultrarapid insulin to fulfill unmet needs in prandial insulin space,"- Olivier Soula, R&D director and deputy general manager ofAdocia
<span id="midArticle_2"/> <span class="second-article-divide"/> <span class="third-article-divide"/>Source text for Eikon: Further company coverage: (Gdynia Newsroom)
<span id="midArticle_3"/>
<span id="midArticle_0"/>* To present positive clinical results for BiochaperoneLispro
<span id="midArticle_1"/> <span class="first-article-divide"/>* "These results further confirm potential of our ultrarapid insulin to fulfill unmet needs in prandial insulin space,"- Olivier Soula, R&D director and deputy general manager ofAdocia
<span id="midArticle_2"/> <span class="second-article-divide"/> <span class="third-article-divide"/>Source text for Eikon: Further company coverage: (Gdynia Newsroom)
<span id="midArticle_3"/>
via Smart Health Shop Forum http://ift.tt/1d26Hfw
No comments:
Post a Comment